Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Een gerandomiseerde vergelijking van gepersonaliseerde zorg op basis van stadiëring van hartziekten versus gebruikelijke zorg ter preventie van gebeurtenissen (TRANSFORM)

25 september 2026 bijgewerkt door: Cleerly, Inc.

Een gerandomiseerde vergelijking van gepersonaliseerde zorg op basis van stadiëring van coronaire hartziekten versus gebruikelijke zorg voor primaire preventie van cardiovasculaire voorvallen

TRANSFORM is a prospective, randomized, open blinded endpoint (PROBE), event-driven, pragmatic trial in patients who are at increased risk for atherosclerotic cardiovascular (CV) disease but with no known symptomatic CV disease. The trial tests the hypothesis that a Cleerly Coronary Artery Disease (CAD) Staging System-based care strategy reduces CV events compared with risk factor-based care.

Studie Overzicht

Gedetailleerde beschrijving

Cardiovascular disease (CVD) persists as the leading cause of morbidity and mortality worldwide at high societal cost. The current primary CVD prevention strategy relies upon risk stratification using population health markers such as age, sex, diabetes, hypertension, dyslipidemia and tobacco use, with preventive therapy intensified in higher risk strata. Since these risk factors are indirect surrogate markers of the underlying disease, atherosclerosis, this strategy leads to treatment of individuals with risk factors who do not have atherosclerosis and failure to treat those with significant atherosclerosis who lack risk factors. The current strategy also cannot determine which individuals are inadequately treated despite effective risk factor management (residual risk). With the current approach, the CV death rate is trending upward in the US despite evidence that screening asymptomatic patients reduces CV events and the widespread availability of effective preventive therapies.

This randomized, controlled, pragmatic trial is designed to address the unmet need for better strategies to identify asymptomatic individuals at increased risk for CV events due to atherosclerosis and to personalize their treatment based on CV risk estimates using coronary artery disease (CAD) visualization and quantification.

This study enrolls patients without known symptoms of ASCVD but who are at increased risk for ASCVD due to their age and having diabetes, prediabetes or metabolic syndrome and tests the hypothesis that a CAD Staging System-based care strategy reduces CV events compared with risk factor-based care. The Cleerly CAD Staging System incorporates imaging-based evaluation for coronary atherosclerosis, algorithm-supported pharmacotherapy and personalized education about their CAD.

Studietype

Ingrijpend

Inschrijving (Geschat)

7500

Fase

  • Niet toepasbaar

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Contact Back-up

Studie Locaties

    • Arizona
      • Chandler, Arizona, Verenigde Staten, 85224
        • Werving
        • Chandler Clinical Trials
        • Contact:
          • Muhammad Salim, MD
      • Scottsdale, Arizona, Verenigde Staten, 85260
        • Werving
        • Scottsdale Clinical Trials
        • Contact:
          • Todd Dreitzler, MD
      • Sun City, Arizona, Verenigde Staten, 85381
        • Werving
        • Sun City Research
        • Contact:
          • Juan Rodriguez, MD
      • Tucson, Arizona, Verenigde Staten, 85704
        • Werving
        • Noble Clinical Research
        • Contact:
          • Roxana Rodriguez, MD
    • California
      • Beverly Hills, California, Verenigde Staten, 90210
        • Werving
        • Cardiovascular Research Foundation of Southern California
        • Contact:
          • Ronald P. Karlsberg, MD
      • Beverly Hills, California, Verenigde Staten, 90211
        • Werving
        • Amicis Research: Beverly Hills
        • Contact:
          • Michael Levine, MD
      • Canoga Park, California, Verenigde Staten, 91303
        • Werving
        • Valiance Clinical Research - Canoga Park
        • Contact:
          • Rami Shaarawy
      • Chula Vista, California, Verenigde Staten, 91911
        • Werving
        • Cardiovascular Institute of San Diego
        • Contact:
          • Milind D. Parikh, MD
      • Granada Hills, California, Verenigde Staten, 91324
        • Werving
        • Amicis Research: Granada Hills
        • Contact:
          • Pascal Dabel, MD
      • Huntington Park, California, Verenigde Staten, 90255
        • Werving
        • Valiance Clinical Research: Huntington Park
        • Contact:
          • Philip Kim, MD
      • Indian Wells, California, Verenigde Staten, 92210
        • Werving
        • HALO Diagnostics
        • Contact:
          • John F. Feller, MD
      • La Jolla, California, Verenigde Staten, 92037
        • Werving
        • Scripps Health
        • Contact:
          • Elizabeth Epstein, MD
      • Lancaster, California, Verenigde Staten, 93534
        • Werving
        • Chemidox Clinical Trials
        • Contact:
          • Pamela Dewar-DeSilva, MD
      • Loma Linda, California, Verenigde Staten, 92354
        • Werving
        • Loma Linda University Health
        • Contact:
          • Purvi Parwani, MD
      • Long Beach, California, Verenigde Staten, 90805
        • Werving
        • Long Beach Research Institute
        • Contact:
          • Ashley Duzik, MD
      • Monterey Park, California, Verenigde Staten, 91754
        • Werving
        • Ace Research Institute - Monterey Park
        • Contact:
          • Yu-Hsiang Sam Lee, MD
      • Newhall, California, Verenigde Staten, 91321
        • Werving
        • Amicis Research: Newhall
        • Contact:
          • Thuong Vo, MD
      • Northridge, California, Verenigde Staten, 91324
        • Werving
        • Ace Research Institute: Northridge
        • Contact:
          • Richard Park, MD
      • Northridge, California, Verenigde Staten, 91324
        • Werving
        • Amicis Research: Northridge
        • Contact:
          • Nana Barseghian, MD
      • Northridge, California, Verenigde Staten, 91325
        • Werving
        • Ace Research Institute: Northridge #2
        • Contact:
          • William Y. Josephson, MD
      • Northridge, California, Verenigde Staten, 91325
        • Actief, niet wervend
        • Northridge Clinical Trials
      • Orange, California, Verenigde Staten, 92868
        • Werving
        • University of California- Irvine
        • Contact:
          • Ailin Barseghian El-Farra, MD
      • Palo Alto, California, Verenigde Staten, 94304
        • Werving
        • Stanford Health Care
        • Contact:
          • Sandra Tsai, MD
      • Palo Alto, California, Verenigde Staten, 94304
        • Werving
        • VA Palo Alto
        • Contact:
          • Shriram Nallamshetty, MD
      • San Fernando, California, Verenigde Staten, 91306
        • Werving
        • Amicis Research: San Fernando
        • Contact:
          • Farid Yasharpour, MD
      • Tarzana, California, Verenigde Staten, 91356
        • Werving
        • Valiance Clinical Research - Tarzana
        • Contact:
          • Harpreet Singh, MD
      • Torrance, California, Verenigde Staten, 90502
        • Werving
        • Lundquist Institute for Biomedical Innovation at Harbor - UCLA Medical Center
        • Contact:
          • Suvasini Lakshmanan, MD
      • Valencia, California, Verenigde Staten, 91355
        • Werving
        • Amicis Research: Valencia
        • Contact:
          • Dennis Lewis, MD
      • Valley Village, California, Verenigde Staten, 91607
        • Werving
        • Concierge Clinical Trials
        • Contact:
          • Neal R. Cutler, MD
    • Colorado
      • Aurora, Colorado, Verenigde Staten, 80045
        • Werving
        • University of Colorado
        • Contact:
          • Steve Simon
        • Hoofdonderzoeker:
          • Steve Simon, MD
      • Denver, Colorado, Verenigde Staten, 80218
        • Werving
        • St. Josephs (Intermountain Healthcare)
        • Contact:
          • Christopher Angus, MD
    • Florida
      • Boca Raton, Florida, Verenigde Staten, 33434
        • Werving
        • Flourish Medical Research
        • Contact:
          • Michael Hafran, MD
      • Cross City, Florida, Verenigde Staten, 32628
        • Werving
        • Apex Research
        • Contact:
          • Tamir Salmani, MD
      • Hialeah, Florida, Verenigde Staten, 33012
        • Werving
        • Evolution Research Center
        • Contact:
          • Riquel Gonzalez, MD
      • Jacksonville, Florida, Verenigde Staten, 32209
        • Werving
        • UF Health Jacksonville
        • Contact:
          • Luis Ortega Paz, MD
      • Miami, Florida, Verenigde Staten, 33137
        • Werving
        • BioPhase Research
        • Contact:
          • Julie Cadet-Plassman, MD
      • Miami, Florida, Verenigde Staten, 33135
        • Werving
        • Fiel Wellness Clinical Research LLC
        • Contact:
          • Osvaldo Caroma, MD
      • Miami, Florida, Verenigde Staten, 33155
        • Werving
        • United Clinical Research
        • Contact:
          • Teresa B. Alfonso, MD
        • Contact:
          • Alfonso
      • Miami, Florida, Verenigde Staten, 33173
        • Werving
        • Atlantis Clinical Research, LLC
        • Contact:
          • Leyvi Alvarado Miranda, MD
      • Miami, Florida, Verenigde Staten, 33183
        • Werving
        • Farma Medical Inc.
        • Contact:
          • Ingrid Fernandez-Milian, MD
      • Miami, Florida, Verenigde Staten, 33173
        • Werving
        • Baptist Health Miami Cardiac and Vascular Institute
        • Contact:
          • Jonathan Fialkow, MD
      • Miami, Florida, Verenigde Staten, 33186
        • Werving
        • New Access Research and Medical Center
        • Contact:
          • Sander Fernandez, MD
      • Miami Beach, Florida, Verenigde Staten, 33140
        • Werving
        • Quantum Clinical Trials
        • Contact:
          • Christopher A. Fayeghi, MD
      • Pensacola, Florida, Verenigde Staten, 32504
        • Werving
        • Ascension Sacred Heart
        • Contact:
          • Rohit Amin, MD
      • Pompano Beach, Florida, Verenigde Staten, 33060
        • Werving
        • Clinical Research Center of Florida
        • Contact:
          • Howard S. Koch, MD
      • Tampa, Florida, Verenigde Staten, 33620
        • Werving
        • University of South Florida
        • Contact:
          • Shone Almeida, MD
    • Georgia
      • Augusta, Georgia, Verenigde Staten, 30907
        • Werving
        • Aiyan Diabetes Center
        • Contact:
          • Anthony D. Turner, MD
      • Dunwoody, Georgia, Verenigde Staten, 30338
        • Werving
        • Emory University
        • Contact:
          • Ambar Kulshreshtha, MD
      • Fayetteville, Georgia, Verenigde Staten, 30214
        • Werving
        • Privia Medical Group Georgia LLC -Fayetteville (Javara)
        • Contact:
          • Charlotte Grayson Mathis, MD
      • Lithia Springs, Georgia, Verenigde Staten, 30122
        • Werving
        • Randomize Now- Atlanta West
        • Contact:
          • Millard Collier Jr., MD
      • Macon, Georgia, Verenigde Staten, 31210
        • Werving
        • Randomize Now-Burton Medical
        • Contact:
          • Frederick Burton, MD
      • Norcross, Georgia, Verenigde Staten, 30092
        • Werving
        • Evergreen Clinical Trials
        • Contact:
          • Dmitriy Pelishev, MD
      • Powder Springs, Georgia, Verenigde Staten, 30127
        • Werving
        • Peachtree Clinical Solutions - Noir Research Collective
        • Contact:
          • Karan Raghavan, MD
      • Riverdale, Georgia, Verenigde Staten, 30296
        • Werving
        • Randomize Now, LLC - Noir Research Collective
        • Contact:
          • Claire K. Willie, MD
      • Savannah, Georgia, Verenigde Staten, 31406
        • Werving
        • Privia Medical Group Georgia, LLC (Javara Inc.)
        • Contact:
          • Thomas G. Moriarity, MD
      • Thomasville, Georgia, Verenigde Staten, 31792
        • Werving
        • Privia Medical Group Georgia - Thomasville (Javara)
        • Contact:
          • William L. Cooper, MD
    • Idaho
      • Meridian, Idaho, Verenigde Staten, 83642
        • Werving
        • Care Institute- High Desert
        • Contact:
          • David A. Hinchman, MD
    • Illinois
      • Chicago, Illinois, Verenigde Staten, 60611
        • Werving
        • Northwestern University
        • Contact:
          • Paul C. Cremer, MD
      • Glenview, Illinois, Verenigde Staten, 60026
        • Werving
        • Northshore University Health System
        • Contact:
          • Amit K. Pursnani, MD
    • Indiana
      • Indianapolis, Indiana, Verenigde Staten, 46237
        • Werving
        • Franciscan Physician Network- Indiana Heart Physicians
        • Contact:
          • Ryan P Daly, MD
      • Indianapolis, Indiana, Verenigde Staten, 46202
        • Werving
        • Indiana Medical Research Institute
        • Contact:
          • Arshad P. Malik
    • Iowa
      • West Des Moines, Iowa, Verenigde Staten, 50266
        • Werving
        • MercyOne Iowa Heart Center
        • Contact:
          • Enrico L. Martin, MD
    • Kentucky
      • Edgewood, Kentucky, Verenigde Staten, 41017
        • Werving
        • St Elizabeth Health Care - CRI
        • Contact:
          • Erica Pivato, MD
      • Louisville, Kentucky, Verenigde Staten, 40202
        • Werving
        • UofL Health
        • Contact:
          • Shahab Ghafghazi, MD
    • Louisiana
      • New Orleans, Louisiana, Verenigde Staten, 70127
        • Werving
        • Ascension DePaul Services Research Center
        • Contact:
          • Kristen Thomas, MD
    • Maryland
      • Bowie, Maryland, Verenigde Staten, 20715
        • Werving
        • Flourish Bowie dba Flourish Research
        • Contact:
          • Sara Collins, MD
      • Columbia, Maryland, Verenigde Staten, 21045
        • Werving
        • KUR Research at CMP
        • Contact:
          • William Saway, MD
    • Massachusetts
      • Boston, Massachusetts, Verenigde Staten, 02115
        • Werving
        • Brigham and Women's Hospital
        • Contact:
          • Ron Blankstein, MD
      • Boston, Massachusetts, Verenigde Staten, 02114
        • Werving
        • Massachusetts General Hospital
        • Contact:
          • Pradeep Natarajan, MD
    • Michigan
      • Detroit, Michigan, Verenigde Staten, 48202
        • Werving
        • Henry Ford Hospital
        • Contact:
          • Cori E Russell, MD
      • Ypsilanti, Michigan, Verenigde Staten, 48917
        • Werving
        • Trinity Health Michigan Heart
        • Contact:
          • Ahmad Mizyed, MD
    • Minnesota
      • Minneapolis, Minnesota, Verenigde Staten, 55407
        • Werving
        • Minneapolis Heart Institute Foundation
        • Contact:
          • Michael D. Miedema, MD
    • Missouri
      • St Louis, Missouri, Verenigde Staten, 63110
        • Werving
        • Washington University School of Medicine
        • Contact:
          • Farhan M. Katchi, MD
      • St Louis, Missouri, Verenigde Staten, 63136
        • Werving
        • Saint Louis Heart and Vascular
        • Contact:
          • Gil Vardi, MD
    • Montana
      • Kalispell, Montana, Verenigde Staten, 59901
        • Werving
        • Boeson Research Kalispell
        • Contact:
          • Justin Buls, MD
      • Missoula, Montana, Verenigde Staten, 59804
        • Werving
        • Boeson Research Fort Missoula
        • Contact:
          • Audrey Remmers, MD
    • Nebraska
      • Lincoln, Nebraska, Verenigde Staten, 68506
        • Werving
        • Bryan Heart
        • Contact:
          • Chad E. Travers, MD
    • Nevada
      • Las Vegas, Nevada, Verenigde Staten, 89128
        • Werving
        • Vector Clinical Trials
        • Contact:
          • Bharat R. Mocherla, MD
      • Las Vegas, Nevada, Verenigde Staten, 89102
        • Werving
        • Southwest Medical Associates- Optum Nevada
        • Contact:
          • Tatiana O. Tsvetkova, MD
    • New Jersey
      • Flemington, New Jersey, Verenigde Staten, 08822
        • Werving
        • Advanced Heart and Vascular Institute of Hunterdon
        • Contact:
          • Andrey Espinoza, MD
      • Marlton, New Jersey, Verenigde Staten, 08053
        • Werving
        • Virtua Health, Inc.
        • Contact:
          • Mark T. Finch, MD
      • New Brunswick, New Jersey, Verenigde Staten, 08901
        • Werving
        • Rutgers State University
        • Contact:
          • Sabahat Bokhari, MD
      • Paramus, New Jersey, Verenigde Staten, 07652
        • Werving
        • The Valley Hospital
        • Contact:
          • Himanshu Gupta, MD
      • Teaneck, New Jersey, Verenigde Staten, 07666
        • Werving
        • Holy Name Medical Center
        • Contact:
          • Jaffar Raza, MD
    • New York
      • Brooklyn, New York, Verenigde Staten, 11221
        • Werving
        • Clindove Research
        • Contact:
          • Nelly Cohen, MD
      • Brooklyn, New York, Verenigde Staten, 11226
        • Werving
        • Swift Clinical Research
        • Contact:
          • Manoj Dalmia, MD
      • Jackson Heights, New York, Verenigde Staten, 11372
        • Werving
        • Rasaj Research
        • Contact:
          • Ammara Mushtaq, MD
      • Lake Success, New York, Verenigde Staten, 11042
        • Werving
        • Optum- Long Island NY
        • Contact:
          • Steven Goldberg, MD
      • Mount Kisco, New York, Verenigde Staten, 10549
        • Werving
        • Northwell Health Northern Westchester Hospital
        • Contact:
          • Margaret Andersen, MD
      • New York, New York, Verenigde Staten, 10019
        • Werving
        • Mount Sinai West
        • Contact:
          • Waqas A Malick, MD
      • New York, New York, Verenigde Staten, 10029
        • Werving
        • Mount Sinai
        • Contact:
          • Solomon Bienstock, MD
    • North Carolina
      • Chapel Hill, North Carolina, Verenigde Staten, 27599
        • Werving
        • University of North Carolina at Chapel Hill
        • Contact:
          • Matthew Cavender, MD
      • Durham, North Carolina, Verenigde Staten, 27701
        • Werving
        • Duke University Hospital
        • Contact:
          • William Yancy, MD
      • Durham, North Carolina, Verenigde Staten, 27705
        • Werving
        • Durham Veterans Affairs Medical Center (Durham VAMC)
        • Contact:
          • Hayden Bosworth, MD
      • Fayetteville, North Carolina, Verenigde Staten, 28304
        • Werving
        • Cape Fear Valley Health System (Javara Inc.)
        • Contact:
          • Nafisa Saleem, MD
      • Morehead City, North Carolina, Verenigde Staten, 28557
        • Actief, niet wervend
        • West Clinical Research
      • Winston-Salem, North Carolina, Verenigde Staten, 27157
        • Werving
        • Wake Forest University Health Sciences
        • Contact:
          • Michael Shapiro, MD
    • North Dakota
      • Fargo, North Dakota, Verenigde Staten, 58102
        • Werving
        • Sanford Health
        • Contact:
          • David J. Clardy, MD
    • Ohio
      • Akron, Ohio, Verenigde Staten, 44304
        • Werving
        • Summa Health
        • Contact:
          • Wissam Alajaji, MD
    • Oklahoma
      • Oklahoma City, Oklahoma, Verenigde Staten, 73109
        • Werving
        • Medical Research International, LLC
        • Contact:
          • Joseph Grillo, MD
      • Oklahoma City, Oklahoma, Verenigde Staten, 73007
        • Werving
        • Hightower Clinical
        • Contact:
          • Faisal Latif, MD
      • Tulsa, Oklahoma, Verenigde Staten, 74104
        • Werving
        • Ascension St. John - Jane Phillips Medical Center
        • Contact:
          • Michael Megaly, MD
    • Pennsylvania
      • Camp Hill, Pennsylvania, Verenigde Staten, 17011
        • Werving
        • Capital Area Research
        • Contact:
          • Venkatesh Nadar, MD
    • South Carolina
      • Charleston, South Carolina, Verenigde Staten, 29425
        • Werving
        • Medical University of South Carolina
        • Contact:
          • Marc-Andre Cornier, MD
    • Tennessee
      • Cleveland, Tennessee, Verenigde Staten, 37312
        • Werving
        • Community DPC
        • Contact:
          • Carlton Volberg, MD
      • Knoxville, Tennessee, Verenigde Staten, 37920
        • Werving
        • University of Tennessee Medical Center
        • Contact:
          • Kashif A. Shaikh, MD
      • Nashville, Tennessee, Verenigde Staten, 37202
        • Werving
        • TriStar Centennial Medical Center (HCA Health Care)
        • Contact:
          • David Huneycutt, MD
    • Texas
      • Abilene, Texas, Verenigde Staten, 79601
        • Werving
        • Hendrick Health
        • Contact:
          • Ren Zhang, MD
      • Beaumont, Texas, Verenigde Staten, 77702
        • Werving
        • Gadolin Research
        • Contact:
          • John T Fowler, MD
      • Greenville, Texas, Verenigde Staten, 75402
        • Werving
        • CardioVoyage, LLC
        • Contact:
          • Marc Demyun, MD
      • Houston, Texas, Verenigde Staten, 77025
        • Werving
        • Kelsey Research Foundation
        • Contact:
          • Rohan R Wagle, MD
      • Houston, Texas, Verenigde Staten, 77004
        • Werving
        • Helium Research Group
        • Contact:
          • Ijeoma A. Ekeruo
      • Houston, Texas, Verenigde Staten, 77070
        • Werving
        • Gulf Coast Clinical Research, LLC
        • Contact:
          • Anjani Pandya, MD
      • Houston, Texas, Verenigde Staten, 77030
        • Werving
        • The Methodist Hospital, DeBakey Cardiology Associates
        • Contact:
          • Sadeer Al-Kindi, MD
      • Laredo, Texas, Verenigde Staten, 78041
        • Werving
        • Aeres Clinical Research
        • Contact:
          • Amando Garza, MD
      • Lewisville, Texas, Verenigde Staten, 75057
        • Werving
        • DC Clinical Research
        • Contact:
          • Moiz M. Shafiq, MD
      • McKinney, Texas, Verenigde Staten, 75069
        • Werving
        • North Dallas Research Associates - Kerlo Network
        • Contact:
          • Muhammad Akram Khan, MD
      • Mesquite, Texas, Verenigde Staten, 75149
        • Werving
        • SMS Clinical Research
        • Contact:
          • Salma Saiger, MD
      • San Marcos, Texas, Verenigde Staten, 78666
        • Werving
        • Privia Medical Group Gulf Coast, PLLC ( Javara Inc.)
        • Contact:
          • Alan Lee, MD
      • Stephenville, Texas, Verenigde Staten, 76401
        • Werving
        • Privia Medical Group- North Texas
        • Contact:
          • Benjamin Marcum, MD
    • Utah
      • West Valley City, Utah, Verenigde Staten, 84120
        • Nog niet aan het werven
        • Kalo Clinical Research
        • Contact:
          • William J. Walsh, MD
    • Virginia
      • Richmond, Virginia, Verenigde Staten, 23225
        • Werving
        • Chippenham Johnston Willis Medical Center
        • Contact:
          • Michael Arcarese, MD
    • Washington
      • Everett, Washington, Verenigde Staten, 98201
        • Werving
        • Providence Regional Medical Center Everett
        • Contact:
          • Xiaojing Jennie Shen, MD
      • Seattle, Washington, Verenigde Staten, 98195
        • Werving
        • University of Washington
        • Contact:
          • Kelley Branch, MD
    • West Virginia
      • Charleston, West Virginia, Verenigde Staten, 25304
        • Werving
        • Charleston Area Medical Center
        • Contact:
          • Sarah Rinehart, MD

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

55 jaar en ouder (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Ja

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  1. Provided electronic or written informed consent

  2. Men > 55, women > 65 years of age

  3. Type 2 diabetes mellitus requiring pharmacologic therapy, prediabetes (most recent HbA1c 5.7 to 6.4% and/or fasting glucose 100-125 mg/dL [5.6-6.9 mmol/L]) and/or metabolic syndrome. Metabolic syndrome is defined as > 3 of the following criteria (International Diabetes Federation 2006):

    • Body mass index ≥ 27 kg/m2 or abnormal waist circumference defined as ≥ 80 cm (31.5 inches) for women, ≥ 94 cm (37 inches) for men; for South and East Asian men (e.g., Asian Indian, Chinese, Japanese) ≥ 90 cm (35.4 inches)
    • Fasting triglycerides ≥ 150 mg/dL (1.7 mmol/L) or treated hypertriglyceridemia
    • HDL-cholesterol (HDL-C) < 40 mg/dL (1.03 mmol/L) in men, <50 mg/dL (1.29 mmol/L) in women or treatment for this lipid abnormality
    • Systolic blood pressure (BP) ≥ 130 and/or diastolic BP≥ 85 mm Hg and/or treated hypertension
    • Fasting blood glucose ≥ 100 mg/dL (5.6 mmol/L) or HbA1c ≥ 5.7%
  4. Have a device (e.g., smartphone, tablet, computer) for communication with the central cardiologist-led team managing drug treatment for the personalized care group

Exclusion Criteria:

  1. History of symptomatic CVD defined as prior MI, exertional or unstable angina, ischemic stroke, claudication, arterial revascularization for atherosclerosis or other CVD being actively managed by a cardiologist, e.g. atrial fibrillation, heart failure

  2. Planned arterial revascularization

  3. Inability to complete screening CCTA or any condition that would increase the risk associated with CCTA or increase likelihood of uninterpretable scan including:

    1. eGFR < 60 mL/min/1.73 m2 by the Chronic Kidney Disease Epidemiology Collaboration (CKD EPI) or Modification of Diet in Renal Disease (MDRD) equation (www.kidney.org/professionals/kdoqi/gfr_calculator)
    2. Allergy to iodinated contrast or history of contrast-induced nephropathy (including adverse reaction to contrast at screening CCTA) or screening laboratory values consistent with untreated hyperthyroidism. Participants with elevated thyroid-stimulating hormone (TSH) may be enrolled but should be referred to their physician for evaluation for treatment.
    3. Thyroid cancer in the previous five (5) years or planned radioactive iodine treatment
    4. Weight > 300 lbs. (136 kg) or above manufacturer-recommended limit for scanner and table at the site
    5. Inability to hold breath for > 10 seconds
    6. Active arrhythmia (atrial fibrillation, atrial flutter, frequent premature atrial, or ventricular contractions) with poorly controlled rate (i.e., > 80 beats per minute at screening or prior to CCTA)
    7. Contraindication to dosing with beta blocker or nitroglycerin on day of screening CCTA
    8. Any other factor that, in the opinion of the investigator, would increase participant risk or increase the chance of an uninterpretable CCTA
  4. Unsuitable as a trial participant in the opinion of the investigator for reasons including significant left main stenosis (e.g. ≥ 70%; site will be notified by Cleerly), other health condition with life expectancy < 3 years or being at risk of poor compliance with study procedures (e.g., active substance abuse or untreated mental illness that, in the opinion of the investigator, is likely to adversely affect adherence or retention)

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Preventie
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Geen tussenkomst: Risk Factor-Based Care

The risk factor-based care group will be managed by their usual care providers, with an initial pre-randomization assessment of current treatment by a centralized cardiology team to optimize care relative to primary prevention guidelines. During the trial, the centralized cardiology team will monitor the provision of medications prescribed and lab values relative to guidelines, and provide feedback and education to site investigators to support optimization. CCTA results will be centrally archived and will remain blinded to the usual care provider until the end of the study.

Experimenteel: Cleerly Stage-Based Care

The Cleerly Stage-Based Care group will receive personalized care centrally managed by a remote cardiologist-led team. They will also receive an initial pre-randomization assessment of current treatment by a centralized cardiology team to optimize care relative to primary prevention guidelines. Cleerly CAD Staging System results will be discussed with participants and serve as the basis for standardized algorithm-supported pharmacotherapy & education, which will be intensified if plaque burden has progressed at 24 months.

The Cleerly CAD Staging System is software that utilizes a proprietary algorithm to identify CAD, stage the severity of CAD when present, and generate a prognostic risk score to inform treatment decisions that support CV disease prevention.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
The primary objective is to compare Cleerly stage-based care with risk factor-based care on the risk of CV events.
Tijdsspanne: Through study completion- an average of 3.5 years

The primary endpoint is total (first and subsequent) events for the composite endpoint of CV death, myocardial infarction (MI), ischemic stroke, acute limb ischemia, clinically driven arterial revascularization, and hospitalization or urgent visit for heart failure.

Through study completion- an average of 3.5 years

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
The secondary objective is to compare Cleerly CAD stage-based care with risk factor-based care on other clinical events of CV and renal morbidity and mortality.
Tijdsspanne: Through study completion- an average of 3.5 years

The secondary endpoints are time from randomization to first occurence of an event in the primary efficacy endpoint.

Through study completion- an average of 3.5 years
The secondary objective is to compare Cleerly CAD stage-based care with risk factor-based care on other clinical events of CV and renal morbidity and mortality.
Tijdsspanne: Through study completion- an average of 3.5 years

The secondary endpoints are total occurences after randomization of the primary efficacy endpoing, kidney failure, sustained estimated glomerular filtration rate (eGFR) decrease >40% from baseline, and death from renal causes.

Through study completion- an average of 3.5 years
The secondary objective is to compare Cleerly CAD stage-based care with risk factor-based care on other clinical events of CV and renal morbidity and mortality.
Tijdsspanne: Through study completion- an average of 3.5 years

The secondary endpoints are first and total occurrences after randomization of coronary death, MI, and urgent coronary revascularization.

Through study completion- an average of 3.5 years
The secondary objective is to compare Cleerly CAD stage-based care with risk factor-based care on other clinical events of CV and renal morbidity and mortality.
Tijdsspanne: Through study completion- an average of 3.5 years

The secondary endpoints are time from randomization to first occurrence of MI or ischemic stroke.

Through study completion- an average of 3.5 years
The secondary objective is to compare Cleerly CAD stage-based care with risk factor-based care on other clinical events of CV and renal morbidity and mortality.
Tijdsspanne: Through study completion- an average of 3.5 years

The secondary endpoints are time from randomization to all-cause death.

Through study completion- an average of 3.5 years

Andere uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
The safety objective is to assess harm with the 2 prevention strategies
Tijdsspanne: Through study completion- an average of 3.5 years

The safety endpoints are Adverse events (AE) leading to discontinuation of study-recommended medication (DAE), serious AE (SAE), adverse device effect (ADE).

Through study completion- an average of 3.5 years
The safety objective is to assess harm with the 2 prevention strategies
Tijdsspanne: Through study completion- an average of 3.5 years

The safety endpoints are 20-item Short Form survey (SF-20).

Through study completion- an average of 3.5 years

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Sponsor

Medewerkers

Onderzoekers

  • Studie stoel: Deepak Bhatt, MD, MPH, Mt. Sinai Heart
  • Studie stoel: David J. Maron, MD, FASPC, Stanford University

Publicaties en nuttige links

De persoon die verantwoordelijk is voor het invoeren van informatie over het onderzoek stelt deze publicaties vrijwillig ter beschikking. Dit kan gaan over alles wat met het onderzoek te maken heeft.

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

6 maart 2024

Primaire voltooiing (Geschat)

5 maart 2029

Studie voltooiing (Geschat)

5 maart 2029

Studieregistratiedata

Eerst ingediend

2 oktober 2023

Eerst ingediend dat voldeed aan de QC-criteria

31 oktober 2023

Eerst geplaatst (Werkelijk)

1 november 2023

Updates van studierecords

Laatste update geplaatst (Werkelijk)

28 september 2026

Laatste update ingediend die voldeed aan QC-criteria

25 september 2026

Laatst geverifieerd

1 september 2026

Meer informatie

Termen gerelateerd aan deze studie

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

NEE

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Ja

product vervaardigd in en geëxporteerd uit de V.S.

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren